GlassScriptPhysician profile
Rajeev Khanna
NPI 1609886712
$8,876.57
in general payments reported to CMS, 2019-2025
36 companies · $950 in 2025
The $950 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $1,891 · 2021: $1,442 · 2022: $1,455 · 2023: $1,256 · 2024: $1,127 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,239.58 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,088.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,808.28 | 2019-2025 | Farxiga, Breztri |
| Davol INC. | $1,000.00 | 2020 | |
| Abbvie INC. | $859.76 | 2019-2025 | |
| Amgen INC. | $477.31 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $420.33 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $229.02 | 2019-2022 | |
| Pfizer INC. | $203.13 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $183.32 | 2020-2022 | |
| Esperion Therapeutics, INC. | $174.32 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $156.79 | 2022-2025 | |
| Astellas Pharma US INC | $127.99 | 2022-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.69 | 2020-2025 | Jardiance |
| Dexcom, INC. | $108.10 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $105.69 | 2024-2025 | Voquezna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $103.93 | 2022-2025 | |
| Amarin Pharma, INC. | $94.11 | 2020-2021 | |
| Genentech USA, INC. | $92.57 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $84.37 | 2019-2022 | |
| Shire North American Group INC | $54.18 | 2019 | |
| Allergan, INC. | $53.38 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $46.65 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $44.67 | 2019 | |
| Medtronic, INC. | $26.26 | 2021 | |
| Mylan Specialty L.P. | $21.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.81 | 2024 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $18.91 | 2019 | |
| Hikma Pharmaceuticals USA | $18.01 | 2019 | |
| Eisai INC. | $16.79 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.31 | 2024 | Unithroid |
| Vistapharm, INC. | $14.41 | 2021 | |
| Biogen, INC. | $13.87 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.70 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.46 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Khanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.